Oxford Cannabinoid Technologies Holdings plc was incorporated as a public limited company on
4 February 2021 with registration number 13179529. OCT is a UK-based pharmaceutical company specialised in cannabinoid drug development. The Companys
vision is to become a global leader in developing licensed prescription medicines that target the
endocannabinoid system and address significant unmet medical needs. The Groups primary market focus
is the total addressable pain market, which is estimated to be worth at least £42.5 billion(1) by
commercialisation of the first drug produced by OCT, currently anticipated to be in 2027, and as such it
initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.
CEO: |
Clarissa Ann Sowemimo- Coke |
Non-Executive Director: |
Indraneil (Neil) Mahapatra |
Executive Director: |
Tim Corn |
Non-Executive Chairman: |
Julie Patricia Pomeroy |
Group Finance Director: |
Paul William Smalley |
Independent Non-Executive Director: |
Charanjit (Cheryl) Dhillon, Lord Mott OBE |
Address: |
Prama House, 267 Banbury Road, Oxford, United Kingdom |
Phone: |
+44 (0) 203 034 2820 |
Fax: |
|
Website: |
http://www.oxcantech.com/ |
Email: |
|